Last updated: July 27, 2025
Introduction
South Korea Patent KR101301558, titled "Method for Treating Autoimmune Diseases Using a Compound", exemplifies innovative pharmaceutical patenting within the context of autoimmune therapy. As South Korea continues to solidify its position as a leading hub for biopharmaceutical research, understanding the patent's scope, claims, and landscape implications provides invaluable insights for industry stakeholders.
This analysis dissects the patent’s technical coverage, claims structure, and its positioning within South Korea’s dynamic patent ecosystem, offering a comprehensive view that informs R&D, licensing, and competitive strategizing.
Patent Overview
KR101301558 was granted in 2013, with a filing date of 2009, reflecting a substantial period of examination aligning with Korean Intellectual Property Office (KIPO) standards. The patent focuses on novel compounds and their use in managing autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and lupus.
The patent covers both compound compositions and methodological applications—specifically the therapeutic use of certain chemical entities with immunomodulatory effects. The inventors likely aimed to secure broad protection, emphasizing both the chemical and functional aspects.
Scope of the Patent: Characteristics and Coverage
The scope encompasses:
- Chemical compounds: Novel molecules, or derivatives thereof, with specific structures characterized by their core scaffolds and functional groups.
- Therapeutic methods: The use of these compounds in the treatment of autoimmune diseases, including dosage forms and treatment regimens.
- Biological activity: Evidence or claims relating to immune response modulation, reducing inflammation, or specific biomarker targeting.
Notably, the claims extend to intermediates, pharmaceutical compositions, and methods of administration, enabling comprehensive coverage of the invention lifecycle.
Claims Analysis
1. Independent Claims
The independent claims chiefly define:
- The chemical structure of the novel compound, often structured as a Markush group covering a class of compounds with certain substituents.
- The method of therapy, asserting the use of these compounds in inhibiting or modulating immune responses characteristic of autoimmune diseases.
- Specific embodiments include dosage ranges, formulations, and treatment protocols, providing tactical coverage for clinical applications.
2. Dependent Claims
Dependent claims narrow or specify the scope:
- They specify particular substituents or modifications to the base compound, improving patent defensibility.
- Embody preferred embodiments such as particular dosage forms or combinations with other drugs.
- Include biological data supporting efficacy, which bolsters the operational scope.
3. Claim Strategies
The patent employs a typical "oil-and-water" claim structure—broad claims for maximum coverage, detailed dependent claims to cover specific embodiments, and use claims focusing on methods and compositions. This multi-layered approach minimizes the risk of patent invalidation while maximizing commercial leverage.
Patent Landscape and Competitive Positioning
1. Patent Family and Related Applications
KR101301558 is part of a broader patent family, with filings in principal markets such as the U.S., Europe, China, and Japan. These related patents collectively fortify the patent holder’s global position, especially given the competitive landscape in autoimmune therapeutics.
2. Prior Art and Novelty
The patent differentiates itself through:
- The unique chemical structure, which appears to be a derivative or novel combination not previously disclosed in prior art.
- Innovative therapeutic claims that demonstrate specific biological activity relevant to autoimmune diseases.
- The utilization method, especially if supported by experimental data, highlights inventive step.
Existing prior art includes older immunomodulatory agents and research compounds, but KR101301558’s specific chemical entities and combination claims carve out a distinctive niche.
3. Competitive Landscape
South Korea's biopharmaceutical sector has several firms active in autoimmune drugs, such as Hanmi Pharmaceutical and Celltrion. The patent positions its holder to compete in this space, especially if subsequent patents expand on this foundation or if licensing negotiations unfold with global pharma entities targeting autoimmune therapies.
Legal and Strategic Considerations
- Strength of claims: Given detailed structural features and therapeutic methods, the patent exhibits strong defensibility, assuming prior art searches confirm novelty.
- Potential challenges: Competitors might seek to design around by developing structurally similar compounds outside the claimed scope or by alternative therapeutic mechanisms.
- Patent lifecycle: The patent, granted in 2013, potentially expires in 2033, assuming standard 20-year terms from filing.
Publication and patent tip: Keeping abreast of amendments or subsequent filings, such as Patent Term Extensions or divisional applications, is crucial for ongoing strategic planning.
Conclusion
KR101301558 represents a strategic patent clearly delineating the chemical and therapeutic scope for a class of compounds aimed at autoimmune diseases. Its claims' breadth, supported by biological identifiers and application methods, secure considerable territory in South Korea’s biologics market and beyond. For industry players, understanding its claims and positioning facilitates both defensive patenting and potential licensing or commercialization opportunities.
Key Takeaways
- The patent covers novel chemical structures and methods for treating autoimmune diseases, with detailed claim nesting to maximize scope.
- Its comprehensive patent landscape, with family member filings, ensures broader protection in key markets.
- The strategic value lies in its ability to block competitors, support licensing, and underpin future innovation.
- Maintaining vigilance over potential infringement or design-arounds is vital, given the patent's structural and therapeutic breadth.
- The patent’s expiry around 2033 offers a window for commercialization and partnerships within its active period.
FAQs
1. What are the critical elements that make KR101301558 a robust patent?
Its patentability hinges on the novel chemical structures, specific therapeutic claims supported by data, and comprehensive scope covering compounds, compositions, and treatment methods, creating a formidable barrier to competitors.
2. How does the patent landscape influence the potential for licensing deals?
A broad patent family across major jurisdictions enhances licensing appeal by reducing infringement risks and providing territorial exclusivity, which can attract collaboration with global pharma companies.
3. Can competitors circumvent this patent, and how?
Yes. They could develop structurally similar compounds outside the claim scope, alter substitution patterns, or pursue different therapeutic pathways by avoiding the specific structural features and claims.
4. What are the strategic implications for a company holding this patent?
It offers a defensive IP asset, opportunities for collaboration, and a platform to further develop related compounds, providing leverage in negotiations and market entry.
5. How do changes in Korean patent law affect patents like KR101301558?
Legal provisions, such as patent term extensions, data exclusivity, and allowance for challenging patents, influence patent strength and lifecycle management, critical for maintaining market advantage.
References
- Korean Intellectual Property Office (KIPO). Patent KR101301558.
- WIPO PatentScope. Patent family data.
- Industry reports on autoimmune drug patent trends.
- Relevant legal statutes governing patent term and validation in South Korea.
